Telehealth GLP-1 Clinic — Type A
GP-led telehealth model focused exclusively on GLP-1 prescribing for chronic weight management under TGA-approved indications.
- Medical oversight4.6 / 5
- Transparency4.3 / 5
- Access clarity4.5 / 5
- Pricing clarity4.2 / 5
- Support clarity4.4 / 5
- Aftercare4.4 / 5
Strengths
- GP-led with structured medical intake
- TGA-approved compounds only
- Australian-registered pharmacy supply chain
- Ongoing review cadence built into the service
Concerns
- Upselling pressure can creep in around quarterly reviews
- Eligibility criteria sometimes loosely applied
- Cost of indefinite prescription is rarely modelled for the patient
Editorial review
This category covers GP-led telehealth services that focus on chronic weight management using TGA-approved GLP-1 receptor agonists. The defining feature: prescriptions are issued by Australian-registered medical practitioners after structured medical intake, typically with ongoing reviews monthly or quarterly.
Strong examples publish their clinical eligibility criteria up-front, route prescriptions through Australian-registered pharmacies, and include progress reviews in their service. Weak examples skip the medical review step, push pre-built protocols, or upsell unrelated peptides outside the GLP-1 class.
What to look for: AHPRA-registered prescribers visible on the site, a structured medical intake (not just a quick form), pricing that breaks down medication vs consultation vs follow-up, and clear policies for when treatment should be paused or stopped.
Compounds typically prescribed
- GLP-1 receptor agonists (Semaglutide, Tirzepatide)
- Adjunct metabolic care
Typical eligibility
- Adults meeting BMI thresholds for chronic weight management
- No contraindications (e.g. personal/family thyroid C-cell history)
- Willing to complete medical intake and ongoing reviews
FAQs
Comparing models? Browse the full clinic hub.
See all clinic profiles